January 31, 2018

Justifying ROI for QbD

Bikash Chatterjee, President & CSO

Within the last year we have seen our share of quality issues hit the airwaves. The troubles in India with Ranbaxy and Wockhardt have spurred some excellent discussion of how to drive the concepts of quality home within pharma.


September 30, 2018

Quality Circle: Profitability, Integrity and the Cost of Poor Quality

Bikash Chatterjee, President & CSO

As major blockbuster drugs come off patent, the scramble among generics to capture these new markets is just beginning. We can expect the U.S. market to experience continued change and consolidation with cost cutting remaining at the top of the priority list for big pharma.